Nathalie Silva de Morais

Nathalie Silva de Morais

Auto-generated profile, based on publicly available information

Nathalie Silva de Morais

Programa de Pós-graduação em Endocrinologia, Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2019 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
NMNathalie Silva de Morais
Nathalie Silva de Morais
JSJessica Stuart
Jessica Stuart
HGHaixia Guan
Haixia Guan
ZWZhihong Wang
Zhihong Wang
ECEdmund S Cibas
Edmund S Cibas
EAErik K Alexander
Erik K Alexander
Introduction The impact of Hashimoto’s thyroiditis (HT) upon the risk of thyroid cancer and its accurate detection remains unclear. Prior studies are limited by retrospective design, selection bias, or their narrow definitions of HT. Importantly, the presence of a chronic lymphocytic infiltration imparts a logical mechanism potentially altering neoplastic transformation, while also influencing the accuracy of diagnostic evaluation. Methods We performed a prospective, cohort analysis studying 9,851 consecutive patients with 21,397 nodules ≥1cm who underwent nodule evaluation between 1995-2017. The definition of HT included a) elevated thyroid peroxidase antibody (TPOAb) and/or, b) findings of diffuse heterogeneity on ultrasound, and/or c) the finding of diffuse lymphocytic thyroiditis on histopathology. We then determined the impact of HT on the distribution of cytology, and ultimately upon malignancy risk. Results 2,651 patients (27%) were diagnosed with HT. In total, 3,895 HT nodules, and 10,168 non-HT nodules, were biopsied. The prevalence of indeterminate and malignant cytology was higher in the HT vs. non-HT group (Indeterminate 26.3% vs. 21.8%, p<0.001; Malignant: 10.0% vs. 6.4%, p<0.001). Ultimately, the risk of any nodule proving malignant was significantly elevated in the setting of HT (RR=1.6 95% CI: 1.44-1.79 p< 0.001). This increased prevalence was maintained when patients with solitary or multiple nodules were analyzed separately (HT vs. non-HT: 24.5% vs. 16.3% solitary; 22.1% vs. 15.4% multinodular, p<0.01). Conclusion Hashimoto’s thyroiditis increases the risk of thyroid malignancy in any patient presenting for nodule evaluation. Diffuse sonographic heterogeneity and/or TPOAb positivity should be used for risk assessment at time of evaluation.

7 December 2020 in Thyroid®
Verified
Journal Article
Closed access
NMNathalie Silva de Morais
Nathalie Silva de Morais
DSDébora Ayres Saraiva
Débora Ayres Saraiva
CCCarolina Corcino
Carolina Corcino
TBTatiana Berbara
Tatiana Berbara
ASAnnie Schtscherbyna
Annie Schtscherbyna
PTPatrícia De Fátima Dos Santos Teixeira
Patrícia De Fátima Dos Santos Teixeira
Background: Insufficient or excessive iodine intake during gestation may compromise adaptive mechanisms in maternal thyroid function and lead to adverse pregnancy outcomes. In this context, we aimed to study the effects of maternal iodine status in the first and third trimesters of gestation on obstetric and neonatal outcomes in an iodine-sufficient population in Rio de Janeiro, Brazil. Methods: A total of 214 pregnant women in the first trimester of gestation were enrolled and prospectively followed until delivery between 2014 and 2017. All participants were ≥18 and ≤35 years, had a spontaneous single pregnancy, and had no history of thyroid or other chronic diseases, nor were they taking iodine-containing supplements at enrollment. In the first trimester, we obtained clinical information and determined thyroid function and the urinary iodine concentration (UIC) of the participants. Thyroid function and UIC were reassessed in the third trimester. Iodine status was determined by the median of UIC obtained from six urine spot samples by the inductively coupled plasma mass spectrometry method. Pregnancy and neonatal outcomes and delivery information were obtained from medical records. Results: The median UIC in the whole population was 219.7 μg/L. The prevalence of UIC <150 μg/L was 17.2%, and 38.7% had UIC ≥250 μg/L. Gestational diabetes (GDM) was higher in the group with UIC 250–499 μg/L ( n = 77) compared with the group with UIC 150–249 μg/L ( n = 94) (20.3% vs. 9.7%, p < 0.05). Ultimately, UIC ≥250 μg/L was an independent risk factors for GDM (relative risk [RR] = 2.9 [confidence interval, CI = 1.1–7.46], p = 0.027) and hypertensive disorders of pregnancy (HDP) (RR = 4.6 [CI = 1.1–18.0], p = 0.029). Among 196 live-born newborns, lower birth length was observed in infants whose mothers had UIC <150μg/L ( n = 37) in the first trimester compared with those with UIC 150–249 μg/L ( n = 86) (median interquartile range: 48.0 [2.2] vs. 49.0 [4.0] cm, p = 0.01). Maternal UIC <150 μg/L was negatively associated with birth length of newborns (Exp (B) = 0.33 [CI = 0.1–0.9], p = 0.03). Conclusions: In a population whose median iodine intake is sufficient, extensive individual variation occurs. Such abnormalities are associated with increased GDM and HDP when UIC is ≥250 μg/L, and lower infant birth length when UIC is <150 μg/L.

1 September 2014 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
NSNathalie Silva
Nathalie Silva
OSOlga Santos
Olga Santos
FMFelipe Morais
Felipe Morais
IGIlan Gottlieb
Ilan Gottlieb
MHMacelo Hadlich
Macelo Hadlich
PTPatricia de Fátima Teixeira
Patricia de Fátima Teixeira
Objective: Several studies have suggested an association between subclinical hypothyroidism (SCH) and increased cardiovascular risk. The aim of this study was to evaluate the presence of coronary artery disease (CAD) in asymptomatic patients with SCH by measuring the coronary artery calcium score (CACS).Design: A total of 222 asymptomatic subjects (103 SCH and 119 euthyroid (EU)), who were between the ages of 35 and 65 years and had no previous history of CAD, were enrolled for this cross-sectional analysis.Methods: The criteria for SCH included a confirmed normal serum free thyroxine and high TSH levels. Lipid profile, Framingham risk score (FRS) and CACS analyses were performed for all subjects.Results: The SCH and EU groups were comparable with respect to age, gender, BMI and frequency of diabetes, systemic arterial hypertension, hypercholesterolaemia and smoking. There was no difference in the median CACS between the SCH and EU groups. However, in the subgroup of subjects with intermediate/high FRS (AR10y≥10%), CACS was higher in the SCH subjects compared with EU subjects (EU vs SCH, 0.0 (57.0) vs 23.0 (161.5);P=0.045). Multivariate analysis revealed that the risk for CACS >100 was independently associated with male gender, age >55 years, and the presence of simultaneous SCH and AR10y≥10% (OR=87.5 (CI=2.1–3500);P=0.001). Serum TSH was positively correlated with CACS, especially in intermediate/high FRS subjects (rs=0.301,P=0.045).Conclusions: It was demonstrated that SCH represents an additional risk factor for CAD, notably in intermediate and high FRS subjects.

1 August 2018 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
NMNathalie Anne de Oliveira e Silva de Morais
Nathalie Anne de Oliveira e Silva de Morais
AAAnnie Schtscherbyna Almeida de Assis
Annie Schtscherbyna Almeida de Assis
CCCarolina Martins Corcino
Carolina Martins Corcino
DSDébora Ayres Saraiva
Débora Ayres Saraiva
TBTatiana Martins Benvenuto Louro Berbara
Tatiana Martins Benvenuto Louro Berbara
PTPatrícia de Fátima dos Santos Teixeira
Patrícia de Fátima dos Santos Teixeira
Keywords TSH; pregnancy; reference range

1 January 2016 in Endocrine Practice
Verified
Journal Article
Closed access
MCMaria Caroline Alves Coelho
Maria Caroline Alves Coelho
NMNathalie Anne de Oliveira e Silva de Morais
Nathalie Anne de Oliveira e Silva de Morais
ABAndrea Cristiani Beuren
Andrea Cristiani Beuren
CLCristiane Bertolino Lopes
Cristiane Bertolino Lopes
CSCamila Vicente Santos
Camila Vicente Santos
MLMaurício Barbosa Lima
Maurício Barbosa Lima

25 January 2022 in Endocrine Practice
Verified
Journal Article
Closed access
NMNathalie Silva de Morais
Nathalie Silva de Morais
TATrevor E. Angell
Trevor E. Angell
SASara Ahmadi
Sara Ahmadi
EAErik K. Alexander
Erik K. Alexander
PTPatricia de Fátima dos Santos Teixeira
Patricia de Fátima dos Santos Teixeira
EMEllen Marqusee
Ellen Marqusee